W
ARIA

Wealthfront’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Wealthfront’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-54
Closed – – 1542
2015
Q2 		$0 Hold
54
– – ﹤0.01% 1437
2015
Q1 		$0 Hold
54
– – ﹤0.01% 1286
2014
Q4 		$0 Hold
54
– – ﹤0.01% 1138
2014
Q3 		$0 Hold
54
– – ﹤0.01% 746
2014
Q2 		$0 Buy
+54
New +$371 ﹤0.01% 641

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wealthfront's ARIA Position: Q3 2015 in Review

Wealthfront sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2015, closing a stake of 54 shares.

Wealthfront first reported a position in ARIA in Q2 2014 and held it in 5 quarters. The position peaked at $0 in Q2 2015. 175 funds tracked by Wall St. Rank hold ARIA as of Q3 2015.

  • Wealthfront reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Wealthfront sold 54 Ariad Pharmaceuticals Inc shares in Q3 2015.
  • Wealthfront first reported a position in Ariad Pharmaceuticals Inc in Q2 2014 and held it in 5 quarters.
  • Wealthfront's Ariad Pharmaceuticals Inc position peaked at $0 in Q2 2015.
  • 175 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2015.

Based on Wealthfront's 13F filing for Q3 2015, filed 18 Nov 2015.